WASHINGTON — A senior senator is examining whether Medicare’s prescription drug benefit is vulnerable to manipulation by pharmaceutical companies that set very high prices for medications. In a letter Tuesday to Medicare’s top administrator, Sen. Charles Grassley, R-Iowa, said policymakers must ensure the Part D prescription program serving 38 million...